248 related articles for article (PubMed ID: 17320022)
1. Use of intravenous bisphosphonates in osteoporosis.
Civitelli R; Napoli N; Armamento-Villareal R
Curr Osteoporos Rep; 2007 Mar; 5(1):8-13. PubMed ID: 17320022
[TBL] [Abstract][Full Text] [Related]
2. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
[TBL] [Abstract][Full Text] [Related]
3. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
[TBL] [Abstract][Full Text] [Related]
4. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
5. Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.
Sartori L; Adami S; Filipponi P; Crepaldi G
Aging Clin Exp Res; 2003 Aug; 15(4):271-83. PubMed ID: 14661816
[TBL] [Abstract][Full Text] [Related]
6. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
Reginster JY
Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Bobba RS; Beattie K; Parkinson B; Kumbhare D; Adachi JD
Drug Saf; 2006; 29(12):1133-52. PubMed ID: 17147460
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
9. Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.
Reginster JY
Expert Opin Pharmacother; 2005 Oct; 6(13):2301-13. PubMed ID: 16218890
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
Miller PD
Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
[TBL] [Abstract][Full Text] [Related]
11. Comparative adherence to weekly oral and quarterly intravenous bisphosphonates among patients with limited heath literacy who sustained distal radius fractures.
Roh YH; Noh JH; Gong HS; Baek GH
J Bone Miner Metab; 2018 Sep; 36(5):589-595. PubMed ID: 28983705
[TBL] [Abstract][Full Text] [Related]
12. [Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].
Dalle Carbonare L; Bertoldo F; Lo Cascio V
Reumatismo; 2009; 61(1):54-64. PubMed ID: 19370189
[TBL] [Abstract][Full Text] [Related]
13. Osteonecrosis of the jaw.
Sari E; Bulut N; Altundag K
J Am Dent Assoc; 2008 Apr; 139(4):398; author reply 398-400. PubMed ID: 18385020
[No Abstract] [Full Text] [Related]
14. Annual zoledronic acid for osteoporosis.
BMJ Group
Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
[TBL] [Abstract][Full Text] [Related]
15. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
Schimmer RC; Bauss F
Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
[TBL] [Abstract][Full Text] [Related]
16. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ
N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242
[TBL] [Abstract][Full Text] [Related]
17. Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date.
Reginster JY; Malaise O; Neuprez A; Jouret VE; Close P
Drugs Aging; 2007; 24(5):351-9. PubMed ID: 17503893
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate-associated adverse events.
Papapetrou PD
Hormones (Athens); 2009; 8(2):96-110. PubMed ID: 19570737
[TBL] [Abstract][Full Text] [Related]
19. Intravenous zoledronic acid for the treatment of osteoporosis.
Lewiecki EM
Curr Osteoporos Rep; 2008 Mar; 6(1):17-23. PubMed ID: 18430396
[TBL] [Abstract][Full Text] [Related]
20. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
Grbic JT; Landesberg R; Lin SQ; Mesenbrink P; Reid IR; Leung PC; Casas N; Recknor CP; Hua Y; Delmas PD; Eriksen EF;
J Am Dent Assoc; 2008 Jan; 139(1):32-40. PubMed ID: 18167382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
